MedeliX
Start asking

erenumab

Aimovig · ATC code N02CD01

Key facts
Active substance
erenumab
Drug class
Antimigraine
ATC code
N02CD01
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Aimovig 70 mg solution for injection in pre-filled syringe / Aimovig 140 mg solution for injection in pre-filled syringe / Aimovig 70 mg solution for injection in pre-filled pen
Marketing authorisation holder
Novartis Europharm Limited
Information as of
2026-10-28

Key facts

Erenumab is a human monoclonal antibody against the CGRP receptor. It is used for migraine prophylaxis in adults with at least 4 migraine days per month.

What it is used for

  • Prophylaxis of migraine in adults with at least 4 migraine days per month (Aimovig).

Dosing

  • Recommended dose 70 mg every 4 weeks subcutaneously; some patients may benefit from 140 mg every 4 weeks (one 140 mg injection or two 70 mg injections).
  • Consider stopping if there is no response after 3 months; then regularly assess the need to continue.
  • No dose adjustment in mild to moderate renal or hepatic impairment; not studied in the elderly, but no adjustment is required.
  • Self-injection after training into the abdomen, thigh or (by another person) upper arm; rotate injection sites.

Contraindications

  • Hypersensitivity to the active substance or any of the excipients.

Important warnings

  • Patients with certain major cardiovascular diseases were excluded from studies; no safety data are available.
  • Serious hypersensitivity reactions (rash, angioedema, anaphylaxis), sometimes more than one week after treatment; discontinue if they occur.
  • Constipation is common; post-marketing cases with serious complications, including hospitalisation and surgery. Higher risk with a history of constipation or medicines that decrease gut motility.
  • Hypertension has been reported post-marketing. See the full text for further warnings.

Side effects

  • For 70 mg/140 mg: injection site reactions (5.6%/4.5%), constipation (1.3%/3.2%), muscle spasms (0.1%/2.0%) and pruritus (0.7%/1.8%); mostly mild or moderate.
  • Hypersensitivity reactions are also common; frequency not known: oral sores, alopecia, rash.

Interactions

  • No effect on exposure to co-administered medicines is expected; no interaction with oral contraceptives or sumatriptan was observed.

Pregnancy and breastfeeding

  • Limited data; as a precaution, avoid use during pregnancy.
  • Breast-feeding: a risk cannot be excluded in the first days after birth; afterwards only if clinically needed.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • AimovigNovartis Europharm Limited · EMEA/H/C/004447

Source: European Medicines Agency (EMA), product information

Turkey

  • KuzelvaFARMANOVA SAĞLIK HİZMETLERİ LTD. ŞTİ. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 3 more European countries
Iceland
Aimovig
Liechtenstein
Aimovig
Norway
Aimovig

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Aimovig – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/aimovig-epar-product-information_en.pdf
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  3. Wikidata (CC0): ATC N02CD.

Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.